Camber Pharmaceuticals is pleased to announce the addition of Solifenacin Succinate Tablets to its current portfolio.

Solifenacin Succinate Tablets are used to treat symptoms of overactive bladder, such as frequent or urgent urination, and incontinence (urine leakage).

Solifenacin Succinate Tablets from Camber are available in 5 mg and 10 mg strengths. Both strengths are available in 30 and 90 count bottles.

To find out more about Solifenacin Succinate Tablets please visit 

Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.

Articles

Camber Pharmaceuticals Launches Generic Vesicare

 Ever committed to helping reduce overall pharmacy spend for patients and partners, 

 regularly performs clinical audits on its specialty claims. In 2021, the company realized $6.2 million in annualized savings through its dose optimization program, leading to an average savings of $6,173 per optimized dispense.

Specialty drugs now account for 50% or greater of the total prescription spend. In some cases, employer clients are seeing specialty costs account for 60% or even greater of their total drug spend. “As more specialty medications come to market and are prescribed, innovative strategies like our clinical audit programs will be needed to help mitigate the increasing costs,” says 

, manager of clinical programs at AllianceRx Walgreens Pharmacy.

Dose optimization is a clinical audit program designed to directly decrease medication costs. This strategy takes major steps toward protecting a payer’s bottom line by minimizing the number of units (oral, injectable, or infused) dispensed for a prescription while providing the same appropriate dose to the patient. For example, some pharmaceutical manufacturers may charge similar prices for 5- and 10-mg capsules. If a physician writes a prescription for two 5-mg capsules each day, this prescription can be more efficiently and economically dispensed with one 10-mg capsule.

In 2021, the clinical audit team at AllianceRx Walgreens Pharmacy identified and reviewed approximately 300 individual patient cases. “After review, 37% of the cases were determined to be a non-opportunity – mainly due to negative financial impact to the patient, medication discontinuation or dose change. Thirty percent of the cases were successfully intervened upon resulting in an annualized savings of over $6.2 million. In 33% of the cases, the prescriber failed to respond to or declined our request,” Trombatt says.

“With this program, we are striving to help patients reduce the number of tablets or capsules they must take and decrease overall prescription costs,” Trombatt says. “This program minimizes the number of units dispensed for a prescription while providing the appropriate dose to the patient.”

Trombatt says these cost savings demonstrate AllianceRx Walgreens Pharmacy’s overall commitment to reducing health care spending in general. “Medication costs, especially specialty medication costs, continue to grow each year. Specialty pharmacies are in a unique position – we are the last line of defense in managing specialty spend. When it comes to the overall savings we are able to provide in order to lower overall health care costs, any impact we can make to potentially lessen that spend is helpful,” he says.

) provides hope and care for better tomorrows to patients with rare diseases and chronic conditions by delivering medications from its specialty and home delivery pharmacies. Our advanced analytical capabilities, pharmacy expertise and technology solutions enable providers, pharmaceutical manufacturers, and health plans to deliver optimal health outcomes. Through personalized care and clinical programs, along with access to the leading number of limited distribution drugs, patients can get back to what matters most. Headquartered in Orlando, Florida, the company holds several national pharmacy accreditations and has team members across the United States.

AllianceRx Walgreens Pharmacy launched clinical audit programs to prevent waste, improve adherence, reduce spend, and provide outcomes data.

AllianceRx Walgreens Pharmacy Reduces Annual Patient Prescription Costs by $6 Million

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc. On Wednesday, September 21, 2022, NYU Langone accepted the Bernard A. Birnbaum, MD, Quality Leadership Award for superior performance in patient care and the Ambulatory Quality and Accountability Award for excellence in outpatient care. Vizient is the nation’s largest healthcare performance improvement organization, and it counts among its membership 97 percent of academic medical centers in the United States.

“Outstanding quality and safety standards are the hallmarks of our institution, reflecting a culture dedicated to excellence and the best outcomes for our patients no matter where in our system they receive care,” says 

, CEO of NYU Langone Health and dean of NYU Grossman School of Medicine. “No other health system in the country has our aggregate of top quality and safety rankings from respected arbiters, including this most recent leadership designation from Vizient.”

 each placed in the top 10 of the Birnbaum Quality Leadership ranking of specialized complex care medical centers.

The Bernard A. Birnbaum, MD, Quality Leadership Award

The Bernard A. Birnbaum, MD, Quality Leadership Award ranks NYU Langone as No. 1 out of 107 comprehensive academic medical centers for excellence in delivering high-quality inpatient care in 6 domains: safety, mortality, effectiveness, efficiency, patient-centeredness, and equity.

NYU Langone consistently ranks highly in the Quality Leadership Award, but this is the first time since 2015 that the hospital has ranked at the top for both this and the Ambulatory Quality and Accountability Award.

The Ambulatory Quality and Accountability Award

The Ambulatory Quality and Accountability Award from Vizient honors NYU Langone as the No. 1 physician practice out of 55 networks. NYU Langone has been ranked among the top performers in outpatient care every year since the award was created in 2015, in recognition of its excellence in delivering high-quality care in five key domains: access to care, quality, efficiency, continuum of care, and equity. NYU Langone’s outpatient network is made up of more than 320 locations in the New York metropolitan area and in Florida.

“NYU Langone continues to expand the breadth and depth of our services so patients can access the highest-quality primary and specialty care in their own communities,” says 

, senior vice president and vice dean for clinical affairs and strategy, chief clinical officer at NYU Langone. “We are improving overall health by providing the best physicians and services in the communities we serve.”

The fully integrated NYU Langone Health hospital system has been recognized for its unparalleled quality and safety metrics by rating agencies across the board. 

 named NYU Langone the No. 1 hospital in New York and No. 3 in the nation. Earlier this year, NYU Grossman School of Medicine ranked No. 2 in the nation for research on the 2022–23 

 “Best Graduate Schools” list. The combination of the 

 rankings position NYU Langone as the top academic health system in the country devoted to patient care, education, and research.

NYU Langone has also earned an “A” top-safety rating from Leapfrog and a five-star Centers for Medicare and Medicaid Services (CMS) rating for quality, safety, and patient experience. Most recently, NYU Langone Hospital—Brooklyn received Magnet® recognition for excellence in nursing by the American Nurses Credentialing Center. Now all NYU Langone inpatient facilities have this prestigious designation, considered the gold standard for nursing.

NYU Langone Health Receives Awards for Outstanding Quality & Safety

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID® (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA). With this volume-limited launch, Dr. Reddy’s is eligible for first-to-market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.

“We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories. “Bringing a more affordable generic version to market creates greater patient access for this important drug.”

As previously announced, Celgene agreed to provide Dr. Reddy’s with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. in settlement of all outstanding claims of its litigation. The agreed-upon percentages remain confidential. As part of the settlement, Dr. Reddy’s is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.

Dr. Reddy’s Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg, and 25 mg strengths, each in a bottle-count size of 21.

: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: 

Dr. Reddy's Laboratories announces the launch of Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-market, 180-day exclusivity

Pharmacist Moms Group® is pleased to debut their Pharmacist Moms’ badge in partnership with Neuriva, a brain health supplement with naturally sourced ingredients that support key indicators of brain health! The badge is awarded to organizations and brands that advocate for the needs of busy pharmacist women in the United States and support the community so that pharmacists can better take care of themselves, their families, and their patients. 

Neuriva recognizes that pharmacists are trusted sources for health information and education and essential to promoting and protecting the public health and wellbeing of the patients they serve. With a commitment to educating pharmacists and their patients on the importance of brain health, Neuriva is on a mission to enable brains to thrive every day. That’s why Pharmacist Moms Group is pleased to reciprocate Neuriva’s dedicated support with the launch of this badge.

Busy working pharmacists need all the help they can get to support their bodies – including their brains. While at times it may seem impossible to care for anything else on top of professional and personal responsibilities, it is always important to prioritize brain health, and it’s never too early or too late to start! Neuriva is here to support pharmacists – 

Neuriva is a proud supporter of Pharmacist Moms Group.

Announcing Exciting News From A Pharmacist Advocate!

, the platform for medically integrated dispensing of specialty medications, today announced a partnership with the 

 (QCCA) to provide QCCA-affiliated practices with an analytical snapshot of their in-office specialty drug dispensing operations, known as “medically integrated dispensing.” The partnership will enable the 16 members of QCCA’s clinically-integrated oncology network to receive important dispensing-related quality and operational metrics.

“Medically integrated dispensing of specialty therapies is an important aspect of oncology care and we are excited to partner with House Rx to help us better understand how our member practices can improve their existing in-house specialty medication dispensing,” said Mark Nelson, PharmD, Chief Business Development Officer of the Quality Cancer Care Alliance Network (QCCA) and CEO of Northwest Medical Specialties.

All QCCA practices will receive a one-time analysis of their in-office specialty drug dispensing operations utilizing data from the practice’s Electronic Health Record (EHR) and Pharmacy Management System (PMS). QCCA practices who elect to use House Rx’s medically integrated dispensing service will have access to ongoing, real-time dispensing analytics via the House Rx technology platform. Currently, two member practices — 

 — partner with House Rx to manage their in-office medically integrated dispensing programs.

“Medically integrated dispensing brings immense value to patients and practices, but it takes the right combination of dispensing expertise and sophisticated technology to truly be successful,” said Tesh Kullar, President and Co-Founder of House Rx. “We’re applying our expertise in technology to enable community clinics who choose to adopt MID to excel at this care model and offer the best possible patient care.”

Sibel Blau, MD, President & CEO of QCCA and Medical Director at Northwest Medical Specialties, said, “We’ve historically lacked sophisticated technology to successfully optimize the operations and improve the quality of our MID programs over time. House Rx’s analyses will provide the desired visibility into the performance of the MID operations at our QCCA member practices. Insights such as prescribing patterns across providers, time-to-fill rates, success rates for prior authorization submissions, and other key data points will go a long way towards helping our practices improve and optimize their dispensing operations.”

For those practices that don’t currently offer medically integrated dispensing, House Rx’s analysis will showcase opportunities to offer their patients a convenient and efficient way to access the therapies they need.


House Rx and QCCA Partner to Improve Medically Integrated Drug Dispensing at Community Oncology Clinics

New cancer treatment therapies, technologies and innovations continue to be discovered and approved for use at a rapid pace, creating an education challenge for physicians and other healthcare professionals within the complex oncology landscape. Working collaboratively with 

 developed a more efficient way for healthcare professionals to expand their knowledge and share feedback about ongoing advancements. FCS, the Florida oncology practice, will be the first to utilize this new program, which offers focused education for governance-level Board members, disease-state experts and generalists.

The virtual learning platform replaces traditional methods that can be cumbersome and time- consuming for physicians and their medical practice teams. On NCODA’s unique platform, 

, the latest updates and detailed information will be available in real-time and can be accessed quickly, at the user’s convenience.

“As a patient-centered organization that works collaboratively with all stakeholders to enhance oncology care, NCODA is thrilled to bring a new and innovative program to fruition,” says 

, NCODA Founder and Executive Director. “By working with the team at FCS, we are providing a smart-solution to an industry-wide challenge that will soon be available to all NCODA member practices.” NCODA’s 5,000+ membership base includes representation from over 900 practices throughout the U.S. and Canada.

, FCS Chief Medical Officer for Therapeutics and Analytics, said, “Organizing the education and information exchange between providers and other health care stakeholders has been long overdue. 

 will greatly enhance the two-way flow of information in an environment of rapid and unprecedented developments in cancer care and help to enhance overall patient care.“


NCODA is a leading non-profit organization dedicated to empowering medically-integrated oncology practices to deliver positive, patient-centered outcomes by providing leadership, expertise, quality standards, and best practices. For more information about NCODA visit 

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)


Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in prestigious medical schools and research institutes, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Founded in 1984, Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic- based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff.

SOURCE: Florida Cancer Specialists & Research Institute

NCODA and Florida Cancer Specialists & Research Institute Announce New Oncology Stakeholder Education Exchange Program

Earlier this week, Inc. 5000 announced that the 

, a fast-growing network of community oncology practices, is ranked number 107 on its 

, the most prestigious ranking of the fastest-growing private companies in America. AON also received the number eight position in the health services category.

The list represents a one-of-a-kind look at the most successful companies within the economy’s most dynamic segment — its independent businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

“We are honored to be recognized as one of the nation’s fastest-growing private companies by Inc.,” said AON Chief Executive Officer 

. “At AON, we believe the key to accessible and equitable healthcare lies in the strength of community healthcare practices, which is why we strive to support community oncology practices, large and small. This recognition is a reminder that we are taking the right steps in forwarding our mission by providing support and resources for hometown oncology practices and breaking down barriers to cancer care.”

The companies on the 2022 Inc. 5000 list are not only successful, but also demonstrate resilience amid supply chain woes, labor shortages and the ongoing impact of COVID-19. Among the top 500, the average median three-year revenue growth rate soared to 2,144 percent. Together, those companies added more than 68,394 jobs over the past three years.

Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at 

. The top 500 companies are featured in the September issue of Inc. magazine, which will be available on August 23.

“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work and rising to the challenges of today.”

“We are excited to celebrate receiving this esteemed award with our physicians, practices, team members and patients,” said Schonherz. “I’d like to extend an additional congratulations to all companies that are on this year’s Inc. 5000 list.”

 (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success of community oncology. Launched in 2018, the rapidly expanding AON network represents 108 physicians and 86 nurse practitioners and physician assistants practicing across 16 states . The executive management team of AON encompasses more than three decades of oncology practice management experience, enabling physicians to focus on what matters most — providing the highest quality care for patients.

The organization provides unique and comprehensive protocols for managing administrative procedures and enhancing ancillary services for its affiliates. AON is able to aggregate volume and attain economies of scale, as it guides its member physicians and practices through the transition to value-based reimbursement models that improve the patient experience and help to reduce the per-capita cost of cancer care.

AON also provides a unique model of physician-led, community-based oncology management. With services such as a centralized specialty pharmacy, diagnostics, pathology, fully integrated electronic medical records, a care management team and a variety of financial assistance programs, an alliance with AON ensures that patients’ experiences are at the very pinnacle of cancer care today. Learn more at 


Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from 2018 to 2021. To qualify, companies must have been founded and generating revenue by March 31, 2018. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2021. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2018 is $100,000; the minimum for 2021 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places. The top 500 companies on the Inc. 5000 are featured in Inc. magazine’s September issue. The entire Inc. 5000 can be found at 


The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference & Gala is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit 

For more information on the Inc. 5000 Conference & Gala, visit 

AON receives ranking no. 107 among America’s fastest-growing private companies and no. eight among health services.

American Oncology Network Ranks No. 107 on the 2022 Inc. 5000 Annual List

The Centers for Medicare & Medicaid Services (CMS) announced its proposed 

Outpatient Prospective Payment System (OPPS),

 which has sparked concern for the community-oncology advocate 

Despite the Biden-Harris Administration’s goal of increasing health equity across all geographies, promoting healthy competition throughout the healthcare industry and driving toward value-based and patient-centered care, CMS’ proposal for 2023 will undoubtedly cripple community healthcare practices.

Most concerning for community-based practices are the increase in the 

 to the average sale price plus 6% and the rise in Medicare reimbursement rates of 2.7%. While practices affiliated with healthcare systems and hospitals reap the benefits of the OPPS proposals, independent community practices will have to reduce their payment rates to maintain neutrality and receive a decrease in Medicare payments — limiting their ability to continue providing quality care, services and medications to their patients.

“For more rural practices, like many of the community oncology practices we support, these are alarming recommendations,” said AON Chief Executive Offer 

. “If these actions come to fruition in 2023, they have the potential to threaten the success and growth of small-town clinics, which will then suffer financially and struggle to effectively compete with larger practices and healthcare systems that qualify under 340B.”

“Community-based clinics provide high-quality care, services and resources that are affordable and accessible,” said AON Chief Medical Officer and Genesis Cancer and Blood Institute medical oncologist 

. “These practices are critical players in closing the cancer care gap and driving healthcare equity. If they do not receive the support needed to continue providing care in their communities, our healthcare system has done a disservice to them and failed.”

CMS is accepting comments on the proposed OPPS through September 13, 2022 and the final ruling is scheduled for November 2022.

“We encourage practices, providers and networks to comment against the proposed OPPS to safeguard community-based care and keep healthcare affordable and accessible,” said Divers.

For more information about CMS’ 2023 OPPS, visit 

https://www.cms.gov/newsroom/fact-sheets/cy-2023-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center

The new proposal will have grave effects on the sustainability of community oncology practices.

American Oncology Network Comments Against CMS’ 2023 Outpatient Prospective Payment System

Florida Cancer Specialists & Research Institute, LLC

 (FCS) pharmacy experts published in the American Journal of Managed Care® (AJMC®) issues a call to action for the development of improved metrics to help lower costs and better assess the performance of pharmacies that dispense oral oncolytic medications. Entitled, “Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies,” the authors detail proven, predictive markers for successfully managing the care of cancer patients prescribed these specialty drugs.

Oral oncolytics today play a major role in the treatment of patients with many types of cancers, offering clinical benefits and patient conveniences as compared to intravenously administered medications. These novel therapies are playing a key role in converting an increasing number of cancers into chronic diseases, allowing patients to live longer with proper management.

To fully benefit from the long-term use of these expensive therapies, a high level of support from pharmacists, pharmacy technicians and other oncology specialists is required.

FCS Senior Vice President of Pharmacy Services for Rx To Go 

, said, “With our proven, multi-faceted approach, we help patients gain access to therapies, ensure timely delivery, provide one-on-one education, stay in constant communication to ensure medication compliance, and efficiently reduce patient and payer costs.”

“Data from our implementation of quality performance scorecards, workflow strategies and patient and provider satisfaction surveys demonstrate the value of our approach,” said Natasha Khrystolubova, RPh, BPharm, BCOP, FCS Director of Pharmacy Clinical Services for Rx To Go.

However, due to the outdated practices of Pharmacy Benefit Managers (PBMs), Medicare patients, in particular, frequently experience roadblocks to accessing medications as well as increasing out-of-pocket costs that speed their entry into coverage gaps. Additionally, specialty pharmacy providers are not receiving adequate reimbursement.

The authors state, “More discussion and collaboration among all stakeholders are needed to develop a set of metrics applicable to in-house and other specialty pharmacies that dispense oral oncolytics.”

“Medically integrated oncology pharmacies such as FCS’ in-house specialty pharmacy, Rx To Go, provide the expertise and patient-centered support that is essential for attaining optimal outcomes,” said FCS Chief Executive Officer 

. “The predictive markers for success that we have identified through our leadership role in value-based oncology care can serve to efficiently reduce patient and provider costs and positively impact cancer care outcomes.”

, FCS Chief Medical Officer of Therapeutics & Analytics, said, “We call on pharmacy benefit managers, plan sponsors and the Pharmacy Quality Alliance to work with the broader oncology specialty pharmacy community to develop specific performance measures structured to reward, not-penalize, high-performing pharmacies.”

The article, prepared with funding assistance from the Community Oncology Alliance (COA), was co-authored by the following from FCS: Lucio Gordan, MD, Chief Medical Officer of Therapeutics & Analytics, Ray Bailey, BPharm, RPh, Senior Vice President of Pharmacy Services, Natasha Khrystolubova, RPh, BPharm, BCOP, Director of Pharmacy Clinical Services, Roger Orr, PharmD, BCOP, Associate Director, Pharmacy Clinical Services and Trista Auger, RPhT, CPhT, Health Outcomes Assistant.

https://www.ajmc.com/view/defining-appropriate-quality-performance-metrics-for-pharmacies-dispensing-oral-oncology-therapies

https://www.ajmc.com/view/a-call-to-action-oncology-practices-and-patients-need-performance-measures-for-managing-oral-therapies

Press Releases